Chemoprevention of prostate cancer with selenium: An update on current clinical trials and preclinical findings
| Autor: | Anne Christine Goulet, Emmanuelle J. Meuillet, Mark A. Nelson, Jacob D. Kagey, Suzanne Stratton, Durga P. Cherukuri, Bruce Porterfield |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
Oncology Clinical Trials as Topic medicine.medical_specialty business.industry Drug Evaluation Preclinical Eligibility Determination Prostatic Neoplasms Cancer Cell Biology Pharmacology medicine.disease Models Biological Biochemistry Clinical trial Selenium Prostate cancer Sodium Selenite Organoselenium Compounds Internal medicine medicine Humans Vitamin E business Molecular Biology |
| Zdroj: | Journal of Cellular Biochemistry. 91:443-458 |
| ISSN: | 1097-4644 0730-2312 |
| DOI: | 10.1002/jcb.10728 |
| Popis: | Prostate cancer is the most common cancer diagnosed and the second leading cause of cancer-related deaths in men in the United States. The etiological factors that give rise to prostate cancer are not known. Therefore, it is not possible to develop primary intervention strategies to remove the causative agents from the environment. However, secondary intervention strategies with selenium (Se) compounds and other agents represent a viable option to reduce the morbidity and mortality of prostate cancer. In this review, we discuss ongoing clinical trials. In addition, we discuss preclinical mechanistic studies that provide insights into the biochemical and molecular basis for the anti-carcinogenic activity of both inorganic and organic forms of Se. © 2003 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text